glp-1 receptor agonist with dpp-4 inhibitor combination not recommended do combine inhibitors agonists guidance What classes of diabetes do not combine dpp-4 inhibitors
Description
doi: 10.1016/j.isci.2021.103382 46 BarnettA
That includes nausea, reflux, and dehydration risk
It references Wegovy injection doses and Wegovy tablets 25 mg

Mol Metab (2021) 46:101102

However, now that these shortages have been resolved, compounded versions are no longer legally permitted to be made

[DOI] [PMC free article] [PubMed] [Google Scholar] Mller FS, Hegelund ER